English

PALVELLA THERAPEUTICS, INC.

EDGAR

PIRS Current report (8-K) · filed 2026-10-28

107 filing records in this dataset, filed from 2013-08-20 to 2026-10-28. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2024 Q3 · USD

Exact inputs and evidence

Revenue: 0 USD Source

Operating cash flow

-2.74 million USD

2024 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -5447000 USD Source
Operating Cash Flow: -2705000 USD Source

Free cash flow

-2.74 million USD

2024 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -5447000 USD Source
Operating Cash Flow: -2705000 USD Source
Capital Expenditure: -0 USD Source
Capital Expenditure: -0 USD Source

Cash and cash equivalents: 188 million USD 2026-06-30 Source
Exact value

187803000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 14.4 million shares 2026-06-30 Source
Exact value

14395705 shares

Reported share-count change

30.16% · 3.34 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

11059665 shares · 2025-06-30· Source
14395705 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

1.35 million USD

2023-10-01 – 2024-09-30

Exact inputs and evidence

Revenue: 42810000 USD · 2023-01-01 – 2023-12-31 Source
Revenue: 41511000 USD · 2023-01-01 – 2023-09-30 Source
Revenue: 53000 USD · 2024-01-01 – 2024-03-31 Source
Revenue: 0 USD · 2024-04-01 – 2024-06-30 Source
Revenue: 0 USD · 2024-07-01 – 2024-09-30 Source

Net income

-61.7 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -11345000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -41700000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -29000000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -15767000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -21870000 USD · 2026-04-01 – 2026-06-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-28.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 9 of 11 periods available· newest 2023-12-31
Operating income: 11 of 11 periods available· newest 2025-12-31
Net income: 11 of 11 periods available· newest 2025-12-31
Operating cash flow: 11 of 11 periods available· newest 2025-12-31
Capital expenditure: 9 of 11 periods available· newest 2023-12-31
Total assets: 11 of 11 periods available· newest 2025-12-31
Total liabilities: 11 of 11 periods available· newest 2025-12-31
Current assets: 11 of 11 periods available· newest 2025-12-31
Current liabilities: 11 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 11 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 11 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
−USD 24.27 million

Prior period

−USD 17.43 million

2024-01-01 – 2024-12-31
Current period

−USD 41.7 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-41700000 − -17434000 = -24266000 USD

-17434000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-41700000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · PALVELLA THERAPEUTICS, INC. · 2025-12-31 PALVELLA THERAPEUTICS, INC. (edgar:1583648) Year-over-year change in Net income: -24266000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T04:36:40Z Snapshot: 02fca779942537b0a08c935bf55b3c110d58931b501aa7dca65196bda2d05b71 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1583648?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -41700000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1583648/000119312526133372/pvla-20251231.htm#2887760 Filing: 000119312526133372 Input fundies:NetIncome: -17434000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1583648/000119312526133372/pvla-20251231.htm#2755327 Filing: 000119312526133372
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 14.16 million

Prior period

−USD 10.84 million

2024-01-01 – 2024-12-31
Current period

−USD 25 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-25000000 − -10840000 = -14160000 USD

-10840000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-25000000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · PALVELLA THERAPEUTICS, INC. · 2025-12-31 PALVELLA THERAPEUTICS, INC. (edgar:1583648) Year-over-year change in Operating cash flow: -14160000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T04:36:40Z Snapshot: 02fca779942537b0a08c935bf55b3c110d58931b501aa7dca65196bda2d05b71 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1583648?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -25000000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1583648/000119312526133372/pvla-20251231.htm#2888616 Filing: 000119312526133372 Input fundies:OperatingCashFlow: -10840000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1583648/000119312526133372/pvla-20251231.htm#2814798 Filing: 000119312526133372
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue, Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2023 2023-01-01 – 2023-12-31

Revenue USD 42.81 million 100% of revenue
Operating costs Derived USD 54.68 million 128% of revenue
Operating income −USD 11.87 million −28% of revenue
Tax, interest and other Derived −USD 30.56 million −71% of revenue
Net income USD 18.69 million 44% of revenue

Cash

Operating cash flow −USD 13.7 million −32% of revenue
Capital expenditure USD 171,000 0.4% of revenue
Free cash flow Derived −USD 13.87 million −32% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2016 Operating loss: operating costs were 490% of revenue.
2017 Operating loss: operating costs were 158% of revenue.
2018 Operating loss: operating costs were 206% of revenue.
2019 Operating loss: operating costs were 159% of revenue.
2020 Operating loss: operating costs were 216% of revenue.
2021 Operating loss: operating costs were 265% of revenue.
2022 Operating loss: operating costs were 170% of revenue.
2023 Operating loss: operating costs were 128% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2016 2016-01-01 – 2016-12-31	5831000	28590000 Derived	-22759000	40000 Derived	-22799000	-14948000 Derived	Source 2016-01-01 – 2016-12-31: 5831000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -22759000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -22799000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -14388000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 560000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	25275000	39869000 Derived	-14594000	3053000 Derived	-17647000	47804000 Derived	Source 2017-01-01 – 2017-12-31: 25275000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -14594000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -17647000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: 49754000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 1950000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	29101000	59932000 Derived	-30831000	-4077000 Derived	-26754000	-2764000 Derived	Source 2018-01-01 – 2018-12-31: 29101000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -30831000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -26754000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -1066000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 1698000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	46279000	73436000 Derived	-27157000	-1657000 Derived	-25500000	-54929000 Derived	Source 2019-01-01 – 2019-12-31: 46279000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -27157000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -25500000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -52467000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 2462000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	29323000	63244000 Derived	-33921000	3279000 Derived	-37200000	-48622000 Derived	Source 2020-01-01 – 2020-12-31: 29323000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -33921000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -37200000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -45896000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 2726000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	31418000	83249000 Derived	-51831000	-6131000 Derived	-45700000	-8609000 Derived	Source 2021-01-01 – 2021-12-31: 31418000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -51831000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -45700000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -7660000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 949000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	25902000	43942000 Derived	-18040000	9512000 Derived	-27552000	-15881000 Derived	Source 2022-01-01 – 2022-12-31: 25902000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -18040000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -27552000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -14840000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 1041000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	42810000	54679000 Derived	-11869000	-30560000 Derived	18691000	-13874000 Derived	Source 2023-01-01 – 2023-12-31: 42810000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -11869000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: 18691000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -13703000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 171000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 42.8M 2023

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20152015-12-31	Revenue	2931931	Revenue: 2931931 Open source
20162016-12-31	Revenue	5831000	Revenue: 5831000 Open source
20172017-12-31	Revenue	25275000	Revenue: 25275000 Open source
20182018-12-31	Revenue	29101000	Revenue: 29101000 Open source
20192019-12-31	Revenue	46279000	Revenue: 46279000 Open source
20202020-12-31	Revenue	29323000	Revenue: 29323000 Open source
20212021-12-31	Revenue	31418000	Revenue: 31418000 Open source
20222022-12-31	Revenue	25902000	Revenue: 25902000 Open source
20232023-12-31	Revenue	42810000	Revenue: 42810000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

65.3% 2023

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20152015-12-31	Year over year	No prior comparable period	Revenue: 2931931 Open source
20162016-12-31	Year over year	98.9%	Revenue: 5831000 Open source Revenue: 2931931 Open source
20172017-12-31	Year over year	333.5%	Revenue: 25275000 Open source Revenue: 5831000 Open source
20182018-12-31	Year over year	15.1%	Revenue: 29101000 Open source Revenue: 25275000 Open source
20192019-12-31	Year over year	59%	Revenue: 46279000 Open source Revenue: 29101000 Open source
20202020-12-31	Year over year	-36.6%	Revenue: 29323000 Open source Revenue: 46279000 Open source
20212021-12-31	Year over year	7.1%	Revenue: 31418000 Open source Revenue: 29323000 Open source
20222022-12-31	Year over year	-17.6%	Revenue: 25902000 Open source Revenue: 31418000 Open source
20232023-12-31	Year over year	65.3%	Revenue: 42810000 Open source Revenue: 25902000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -27.7% 2023

Net margin 43.7% 2023

Free cash flow margin -32.4% 2023

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20152015-12-31	Operating margin	-466.6%	Operating Income: -13681035 Open source Revenue: 2931931 Open source
20162016-12-31	Operating margin	-390.3%	Operating Income: -22759000 Open source Revenue: 5831000 Open source
20172017-12-31	Operating margin	-57.7%	Operating Income: -14594000 Open source Revenue: 25275000 Open source
20182018-12-31	Operating margin	-105.9%	Operating Income: -30831000 Open source Revenue: 29101000 Open source
20192019-12-31	Operating margin	-58.7%	Operating Income: -27157000 Open source Revenue: 46279000 Open source
20202020-12-31	Operating margin	-115.7%	Operating Income: -33921000 Open source Revenue: 29323000 Open source
20212021-12-31	Operating margin	-165%	Operating Income: -51831000 Open source Revenue: 31418000 Open source
20222022-12-31	Operating margin	-69.6%	Operating Income: -18040000 Open source Revenue: 25902000 Open source
20232023-12-31	Operating margin	-27.7%	Operating Income: -11869000 Open source Revenue: 42810000 Open source
20152015-12-31	Net margin	-479.5%	Net Income: -14058641 Open source Revenue: 2931931 Open source
20162016-12-31	Net margin	-391%	Net Income: -22799000 Open source Revenue: 5831000 Open source
20172017-12-31	Net margin	-69.8%	Net Income: -17647000 Open source Revenue: 25275000 Open source
20182018-12-31	Net margin	-91.9%	Net Income: -26754000 Open source Revenue: 29101000 Open source
20192019-12-31	Net margin	-55.1%	Net Income: -25500000 Open source Revenue: 46279000 Open source
20202020-12-31	Net margin	-126.9%	Net Income: -37200000 Open source Revenue: 29323000 Open source
20212021-12-31	Net margin	-145.5%	Net Income: -45700000 Open source Revenue: 31418000 Open source
20222022-12-31	Net margin	-106.4%	Net Income: -27552000 Open source Revenue: 25902000 Open source
20232023-12-31	Net margin	43.7%	Net Income: 18691000 Open source Revenue: 42810000 Open source
20152015-12-31	Free cash flow margin	Not reported	Revenue: 2931931 Open source
20162016-12-31	Free cash flow margin	-256.4%	Revenue: 5831000 Open source Operating Cash Flow: -14388000 Open source Capital Expenditure: 560000 Open source
20172017-12-31	Free cash flow margin	189.1%	Revenue: 25275000 Open source Operating Cash Flow: 49754000 Open source Capital Expenditure: 1950000 Open source
20182018-12-31	Free cash flow margin	-9.5%	Revenue: 29101000 Open source Operating Cash Flow: -1066000 Open source Capital Expenditure: 1698000 Open source
20192019-12-31	Free cash flow margin	-118.7%	Revenue: 46279000 Open source Operating Cash Flow: -52467000 Open source Capital Expenditure: 2462000 Open source
20202020-12-31	Free cash flow margin	-165.8%	Revenue: 29323000 Open source Operating Cash Flow: -45896000 Open source Capital Expenditure: 2726000 Open source
20212021-12-31	Free cash flow margin	-27.4%	Revenue: 31418000 Open source Operating Cash Flow: -7660000 Open source Capital Expenditure: 949000 Open source
20222022-12-31	Free cash flow margin	-61.3%	Revenue: 25902000 Open source Operating Cash Flow: -14840000 Open source Capital Expenditure: 1041000 Open source
20232023-12-31	Free cash flow margin	-32.4%	Revenue: 42810000 Open source Operating Cash Flow: -13703000 Open source Capital Expenditure: 171000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -13.7M 2023

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20152015-12-31	Operating cash flow	Not reported	No source recorded
20162016-12-31	Operating cash flow	-14388000	Operating Cash Flow: -14388000 Open source
20172017-12-31	Operating cash flow	49754000	Operating Cash Flow: 49754000 Open source
20182018-12-31	Operating cash flow	-1066000	Operating Cash Flow: -1066000 Open source
20192019-12-31	Operating cash flow	-52467000	Operating Cash Flow: -52467000 Open source
20202020-12-31	Operating cash flow	-45896000	Operating Cash Flow: -45896000 Open source
20212021-12-31	Operating cash flow	-7660000	Operating Cash Flow: -7660000 Open source
20222022-12-31	Operating cash flow	-14840000	Operating Cash Flow: -14840000 Open source
20232023-12-31	Operating cash flow	-13703000	Operating Cash Flow: -13703000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -13.9M 2023

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20152015-12-31	Free cash flow	Unavailable	No source recorded
20162016-12-31	Free cash flow	-14948000	Operating Cash Flow: -14388000 Open source Capital Expenditure: 560000 Open source
20172017-12-31	Free cash flow	47804000	Operating Cash Flow: 49754000 Open source Capital Expenditure: 1950000 Open source
20182018-12-31	Free cash flow	-2764000	Operating Cash Flow: -1066000 Open source Capital Expenditure: 1698000 Open source
20192019-12-31	Free cash flow	-54929000	Operating Cash Flow: -52467000 Open source Capital Expenditure: 2462000 Open source
20202020-12-31	Free cash flow	-48622000	Operating Cash Flow: -45896000 Open source Capital Expenditure: 2726000 Open source
20212021-12-31	Free cash flow	-8609000	Operating Cash Flow: -7660000 Open source Capital Expenditure: 949000 Open source
20222022-12-31	Free cash flow	-15881000	Operating Cash Flow: -14840000 Open source Capital Expenditure: 1041000 Open source
20232023-12-31	Free cash flow	-13874000	Operating Cash Flow: -13703000 Open source Capital Expenditure: 171000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

151.4% 2023

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20152015-12-31	Liabilities / assets	8.3%	Total Liabilities: 2821768 Open source Total Assets: 33950061 Open source
20162016-12-31	Liabilities / assets	28.1%	Total Liabilities: 9836000 Open source Total Assets: 35063000 Open source
20172017-12-31	Liabilities / assets	88.9%	Total Liabilities: 92354000 Open source Total Assets: 103876000 Open source
20182018-12-31	Liabilities / assets	71.7%	Total Liabilities: 101406000 Open source Total Assets: 141341000 Open source
20192019-12-31	Liabilities / assets	63.6%	Total Liabilities: 89745000 Open source Total Assets: 141097000 Open source
20202020-12-31	Liabilities / assets	70.5%	Total Liabilities: 73983000 Open source Total Assets: 105010000 Open source
20212021-12-31	Liabilities / assets	66.9%	Total Liabilities: 102805000 Open source Total Assets: 153560000 Open source
20222022-12-31	Liabilities / assets	240.2%	Total Liabilities: 39698000 Open source Total Assets: 16524000 Open source
20232023-12-31	Liabilities / assets	151.4%	Total Liabilities: 11428000 Open source Total Assets: 7548000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

3.2× 2023

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20152015-12-31	Current assets / current liabilities	11.32×	Current Assets: 31660509 Open source Current Liabilities: 2797916 Open source
20162016-12-31	Current assets / current liabilities	3.9×	Current Assets: 32673000 Open source Current Liabilities: 8380000 Open source
20172017-12-31	Current assets / current liabilities	1.96×	Current Assets: 89790000 Open source Current Liabilities: 45775000 Open source
20182018-12-31	Current assets / current liabilities	2.82×	Current Assets: 135382000 Open source Current Liabilities: 48076000 Open source
20192019-12-31	Current assets / current liabilities	4.26×	Current Assets: 115013000 Open source Current Liabilities: 27003000 Open source
20202020-12-31	Current assets / current liabilities	3.42×	Current Assets: 75721000 Open source Current Liabilities: 22145000 Open source
20212021-12-31	Current assets / current liabilities	2.52×	Current Assets: 127625000 Open source Current Liabilities: 50561000 Open source
20222022-12-31	Current assets / current liabilities	2.86×	Current Assets: 16524000 Open source Current Liabilities: 5782000 Open source
20232023-12-31	Current assets / current liabilities	3.2×	Current Assets: 7548000 Open source Current Liabilities: 2360000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	−USD 22.8 million Exact value Exact value: -22799000 USD 2016-01-01 – 2016-12-31: -22799000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PALVELLA THERAPEUTICS, INC. · 2016-12-31 PALVELLA THERAPEUTICS, INC. (edgar:1583648) Net Income: -22799000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T04:36:40Z Snapshot: 02fca779942537b0a08c935bf55b3c110d58931b501aa7dca65196bda2d05b71 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1583648/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -22799000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1583648/000158364818000017/pirs-20171231.xml#192240 Filing: 000158364818000017 The citation records this snapshot. The page link may show a newer release later.	−USD 14.39 million Exact value Exact value: -14388000 USD 2016-01-01 – 2016-12-31: -14388000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PALVELLA THERAPEUTICS, INC. · 2016-12-31 PALVELLA THERAPEUTICS, INC. (edgar:1583648) Operating Cash Flow: -14388000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T04:36:40Z Snapshot: 02fca779942537b0a08c935bf55b3c110d58931b501aa7dca65196bda2d05b71 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1583648/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -14388000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1583648/000158364818000017/pirs-20171231.xml#191737 Filing: 000158364818000017 The citation records this snapshot. The page link may show a newer release later.	USD 560,000 Exact value Exact value: 560000 USD 2016-01-01 – 2016-12-31: 560000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · PALVELLA THERAPEUTICS, INC. · 2016-12-31 PALVELLA THERAPEUTICS, INC. (edgar:1583648) Capital Expenditure: 560000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T04:36:40Z Snapshot: 02fca779942537b0a08c935bf55b3c110d58931b501aa7dca65196bda2d05b71 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1583648/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 560000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1583648/000158364818000017/pirs-20171231.xml#201902 Filing: 000158364818000017 The citation records this snapshot. The page link may show a newer release later.	−USD 14.95 million Calculation and evidence -14388000 − 560000 USD Exact free cash flow: -14948000 USD 2016-01-01 – 2016-12-31: -14388000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 560000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · PALVELLA THERAPEUTICS, INC. · 2016-12-31 PALVELLA THERAPEUTICS, INC. (edgar:1583648) Free cash flow: -14948000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T04:36:40Z Snapshot: 02fca779942537b0a08c935bf55b3c110d58931b501aa7dca65196bda2d05b71 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1583648?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -14388000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1583648/000158364818000017/pirs-20171231.xml#191737 Filing: 000158364818000017 Input fundies:CapitalExpenditure: 560000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1583648/000158364818000017/pirs-20171231.xml#201902 Filing: 000158364818000017 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 17.65 million Exact value Exact value: -17647000 USD 2017-01-01 – 2017-12-31: -17647000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PALVELLA THERAPEUTICS, INC. · 2017-12-31 PALVELLA THERAPEUTICS, INC. (edgar:1583648) Net Income: -17647000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T04:36:40Z Snapshot: 02fca779942537b0a08c935bf55b3c110d58931b501aa7dca65196bda2d05b71 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1583648/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -17647000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1583648/000158364819000011/pirs-20181231.xml#224317 Filing: 000158364819000011 The citation records this snapshot. The page link may show a newer release later.	USD 49.75 million Exact value Exact value: 49754000 USD 2017-01-01 – 2017-12-31: 49754000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PALVELLA THERAPEUTICS, INC. · 2017-12-31 PALVELLA THERAPEUTICS, INC. (edgar:1583648) Operating Cash Flow: 49754000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T04:36:40Z Snapshot: 02fca779942537b0a08c935bf55b3c110d58931b501aa7dca65196bda2d05b71 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1583648/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 49754000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1583648/000158364819000011/pirs-20181231.xml#223895 Filing: 000158364819000011 The citation records this snapshot. The page link may show a newer release later.	USD 1.95 million Exact value Exact value: 1950000 USD 2017-01-01 – 2017-12-31: 1950000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · PALVELLA THERAPEUTICS, INC. · 2017-12-31 PALVELLA THERAPEUTICS, INC. (edgar:1583648) Capital Expenditure: 1950000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T04:36:40Z Snapshot: 02fca779942537b0a08c935bf55b3c110d58931b501aa7dca65196bda2d05b71 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1583648/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1950000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1583648/000158364819000011/pirs-20181231.xml#235002 Filing: 000158364819000011 The citation records this snapshot. The page link may show a newer release later.	USD 47.8 million Calculation and evidence 49754000 − 1950000 USD Exact free cash flow: 47804000 USD 2017-01-01 – 2017-12-31: 49754000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 1950000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · PALVELLA THERAPEUTICS, INC. · 2017-12-31 PALVELLA THERAPEUTICS, INC. (edgar:1583648) Free cash flow: 47804000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T04:36:40Z Snapshot: 02fca779942537b0a08c935bf55b3c110d58931b501aa7dca65196bda2d05b71 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1583648?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 49754000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1583648/000158364819000011/pirs-20181231.xml#223895 Filing: 000158364819000011 Input fundies:CapitalExpenditure: 1950000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1583648/000158364819000011/pirs-20181231.xml#235002 Filing: 000158364819000011 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 26.75 million Exact value Exact value: -26754000 USD 2018-01-01 – 2018-12-31: -26754000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PALVELLA THERAPEUTICS, INC. · 2018-12-31 PALVELLA THERAPEUTICS, INC. (edgar:1583648) Net Income: -26754000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T04:36:40Z Snapshot: 02fca779942537b0a08c935bf55b3c110d58931b501aa7dca65196bda2d05b71 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1583648/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -26754000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1583648/000158364820000015/pirs-20191231.xml#247735 Filing: 000158364820000015 The citation records this snapshot. The page link may show a newer release later.	−USD 1.07 million Exact value Exact value: -1066000 USD 2018-01-01 – 2018-12-31: -1066000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PALVELLA THERAPEUTICS, INC. · 2018-12-31 PALVELLA THERAPEUTICS, INC. (edgar:1583648) Operating Cash Flow: -1066000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T04:36:40Z Snapshot: 02fca779942537b0a08c935bf55b3c110d58931b501aa7dca65196bda2d05b71 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1583648/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1066000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1583648/000158364820000015/pirs-20191231.xml#247312 Filing: 000158364820000015 The citation records this snapshot. The page link may show a newer release later.	USD 1.7 million Exact value Exact value: 1698000 USD 2018-01-01 – 2018-12-31: 1698000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · PALVELLA THERAPEUTICS, INC. · 2018-12-31 PALVELLA THERAPEUTICS, INC. (edgar:1583648) Capital Expenditure: 1698000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T04:36:40Z Snapshot: 02fca779942537b0a08c935bf55b3c110d58931b501aa7dca65196bda2d05b71 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1583648/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1698000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1583648/000158364820000015/pirs-20191231.xml#263686 Filing: 000158364820000015 The citation records this snapshot. The page link may show a newer release later.	−USD 2.76 million Calculation and evidence -1066000 − 1698000 USD Exact free cash flow: -2764000 USD 2018-01-01 – 2018-12-31: -1066000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 1698000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · PALVELLA THERAPEUTICS, INC. · 2018-12-31 PALVELLA THERAPEUTICS, INC. (edgar:1583648) Free cash flow: -2764000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T04:36:40Z Snapshot: 02fca779942537b0a08c935bf55b3c110d58931b501aa7dca65196bda2d05b71 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1583648?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -1066000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1583648/000158364820000015/pirs-20191231.xml#247312 Filing: 000158364820000015 Input fundies:CapitalExpenditure: 1698000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1583648/000158364820000015/pirs-20191231.xml#263686 Filing: 000158364820000015 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 25.5 million Exact value Exact value: -25500000 USD 2019-01-01 – 2019-12-31: -25500000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PALVELLA THERAPEUTICS, INC. · 2019-12-31 PALVELLA THERAPEUTICS, INC. (edgar:1583648) Net Income: -25500000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T04:36:40Z Snapshot: 02fca779942537b0a08c935bf55b3c110d58931b501aa7dca65196bda2d05b71 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1583648/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -25500000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1583648/000158364821000005/pirs-20201231.htm#1654209 Filing: 000158364821000005 The citation records this snapshot. The page link may show a newer release later.	−USD 52.47 million Exact value Exact value: -52467000 USD 2019-01-01 – 2019-12-31: -52467000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PALVELLA THERAPEUTICS, INC. · 2019-12-31 PALVELLA THERAPEUTICS, INC. (edgar:1583648) Operating Cash Flow: -52467000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T04:36:40Z Snapshot: 02fca779942537b0a08c935bf55b3c110d58931b501aa7dca65196bda2d05b71 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1583648/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -52467000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1583648/000158364821000005/pirs-20201231.htm#1602116 Filing: 000158364821000005 The citation records this snapshot. The page link may show a newer release later.	USD 2.46 million Exact value Exact value: 2462000 USD 2019-01-01 – 2019-12-31: 2462000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · PALVELLA THERAPEUTICS, INC. · 2019-12-31 PALVELLA THERAPEUTICS, INC. (edgar:1583648) Capital Expenditure: 2462000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T04:36:40Z Snapshot: 02fca779942537b0a08c935bf55b3c110d58931b501aa7dca65196bda2d05b71 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1583648/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2462000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1583648/000158364821000005/pirs-20201231.htm#1604931 Filing: 000158364821000005 The citation records this snapshot. The page link may show a newer release later.	−USD 54.93 million Calculation and evidence -52467000 − 2462000 USD Exact free cash flow: -54929000 USD 2019-01-01 – 2019-12-31: -52467000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 2462000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · PALVELLA THERAPEUTICS, INC. · 2019-12-31 PALVELLA THERAPEUTICS, INC. (edgar:1583648) Free cash flow: -54929000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T04:36:40Z Snapshot: 02fca779942537b0a08c935bf55b3c110d58931b501aa7dca65196bda2d05b71 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1583648?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -52467000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1583648/000158364821000005/pirs-20201231.htm#1602116 Filing: 000158364821000005 Input fundies:CapitalExpenditure: 2462000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1583648/000158364821000005/pirs-20201231.htm#1604931 Filing: 000158364821000005 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 37.2 million Exact value Exact value: -37200000 USD 2020-01-01 – 2020-12-31: -37200000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PALVELLA THERAPEUTICS, INC. · 2020-12-31 PALVELLA THERAPEUTICS, INC. (edgar:1583648) Net Income: -37200000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T04:36:40Z Snapshot: 02fca779942537b0a08c935bf55b3c110d58931b501aa7dca65196bda2d05b71 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1583648/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -37200000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1583648/000158364822000016/pirs-20211231.htm#1768844 Filing: 000158364822000016 The citation records this snapshot. The page link may show a newer release later.	−USD 45.9 million Exact value Exact value: -45896000 USD 2020-01-01 – 2020-12-31: -45896000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PALVELLA THERAPEUTICS, INC. · 2020-12-31 PALVELLA THERAPEUTICS, INC. (edgar:1583648) Operating Cash Flow: -45896000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T04:36:40Z Snapshot: 02fca779942537b0a08c935bf55b3c110d58931b501aa7dca65196bda2d05b71 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1583648/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -45896000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1583648/000158364822000016/pirs-20211231.htm#1721917 Filing: 000158364822000016 The citation records this snapshot. The page link may show a newer release later.	USD 2.73 million Exact value Exact value: 2726000 USD 2020-01-01 – 2020-12-31: 2726000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · PALVELLA THERAPEUTICS, INC. · 2020-12-31 PALVELLA THERAPEUTICS, INC. (edgar:1583648) Capital Expenditure: 2726000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T04:36:40Z Snapshot: 02fca779942537b0a08c935bf55b3c110d58931b501aa7dca65196bda2d05b71 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1583648/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2726000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1583648/000158364822000016/pirs-20211231.htm#1724715 Filing: 000158364822000016 The citation records this snapshot. The page link may show a newer release later.	−USD 48.62 million Calculation and evidence -45896000 − 2726000 USD Exact free cash flow: -48622000 USD 2020-01-01 – 2020-12-31: -45896000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 2726000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · PALVELLA THERAPEUTICS, INC. · 2020-12-31 PALVELLA THERAPEUTICS, INC. (edgar:1583648) Free cash flow: -48622000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T04:36:40Z Snapshot: 02fca779942537b0a08c935bf55b3c110d58931b501aa7dca65196bda2d05b71 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1583648?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -45896000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1583648/000158364822000016/pirs-20211231.htm#1721917 Filing: 000158364822000016 Input fundies:CapitalExpenditure: 2726000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1583648/000158364822000016/pirs-20211231.htm#1724715 Filing: 000158364822000016 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 45.7 million Exact value Exact value: -45700000 USD 2021-01-01 – 2021-12-31: -45700000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PALVELLA THERAPEUTICS, INC. · 2021-12-31 PALVELLA THERAPEUTICS, INC. (edgar:1583648) Net Income: -45700000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T04:36:40Z Snapshot: 02fca779942537b0a08c935bf55b3c110d58931b501aa7dca65196bda2d05b71 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1583648/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -45700000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1583648/000143774923008834/pirs20221231_10k.htm#1731913 Filing: 000143774923008834 The citation records this snapshot. The page link may show a newer release later.	−USD 7.66 million Exact value Exact value: -7660000 USD 2021-01-01 – 2021-12-31: -7660000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PALVELLA THERAPEUTICS, INC. · 2021-12-31 PALVELLA THERAPEUTICS, INC. (edgar:1583648) Operating Cash Flow: -7660000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T04:36:40Z Snapshot: 02fca779942537b0a08c935bf55b3c110d58931b501aa7dca65196bda2d05b71 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1583648/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -7660000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1583648/000143774923008834/pirs20221231_10k.htm#1694714 Filing: 000143774923008834 The citation records this snapshot. The page link may show a newer release later.	USD 949,000 Exact value Exact value: 949000 USD 2021-01-01 – 2021-12-31: 949000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · PALVELLA THERAPEUTICS, INC. · 2021-12-31 PALVELLA THERAPEUTICS, INC. (edgar:1583648) Capital Expenditure: 949000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T04:36:40Z Snapshot: 02fca779942537b0a08c935bf55b3c110d58931b501aa7dca65196bda2d05b71 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1583648/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 949000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1583648/000143774923008834/pirs20221231_10k.htm#1697047 Filing: 000143774923008834 The citation records this snapshot. The page link may show a newer release later.	−USD 8.61 million Calculation and evidence -7660000 − 949000 USD Exact free cash flow: -8609000 USD 2021-01-01 – 2021-12-31: -7660000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 949000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · PALVELLA THERAPEUTICS, INC. · 2021-12-31 PALVELLA THERAPEUTICS, INC. (edgar:1583648) Free cash flow: -8609000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T04:36:40Z Snapshot: 02fca779942537b0a08c935bf55b3c110d58931b501aa7dca65196bda2d05b71 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1583648?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -7660000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1583648/000143774923008834/pirs20221231_10k.htm#1694714 Filing: 000143774923008834 Input fundies:CapitalExpenditure: 949000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1583648/000143774923008834/pirs20221231_10k.htm#1697047 Filing: 000143774923008834 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 27.55 million Exact value Exact value: -27552000 USD 2022-01-01 – 2022-12-31: -27552000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PALVELLA THERAPEUTICS, INC. · 2022-12-31 PALVELLA THERAPEUTICS, INC. (edgar:1583648) Net Income: -27552000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T04:36:40Z Snapshot: 02fca779942537b0a08c935bf55b3c110d58931b501aa7dca65196bda2d05b71 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1583648/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -27552000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1583648/000143774924038553/pirs20241220_s1.htm#5429111 Filing: 000143774924038553 The citation records this snapshot. The page link may show a newer release later.	−USD 14.84 million Exact value Exact value: -14840000 USD 2022-01-01 – 2022-12-31: -14840000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PALVELLA THERAPEUTICS, INC. · 2022-12-31 PALVELLA THERAPEUTICS, INC. (edgar:1583648) Operating Cash Flow: -14840000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T04:36:40Z Snapshot: 02fca779942537b0a08c935bf55b3c110d58931b501aa7dca65196bda2d05b71 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1583648/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -14840000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1583648/000143774924038553/pirs20241220_s1.htm#5447087 Filing: 000143774924038553 The citation records this snapshot. The page link may show a newer release later.	USD 1.04 million Exact value Exact value: 1041000 USD 2022-01-01 – 2022-12-31: 1041000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · PALVELLA THERAPEUTICS, INC. · 2022-12-31 PALVELLA THERAPEUTICS, INC. (edgar:1583648) Capital Expenditure: 1041000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T04:36:40Z Snapshot: 02fca779942537b0a08c935bf55b3c110d58931b501aa7dca65196bda2d05b71 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1583648/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1041000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1583648/000143774924010123/pirs20231231_10k.htm#1271122 Filing: 000143774924010123 The citation records this snapshot. The page link may show a newer release later.	−USD 15.88 million Calculation and evidence -14840000 − 1041000 USD Exact free cash flow: -15881000 USD 2022-01-01 – 2022-12-31: -14840000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 1041000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · PALVELLA THERAPEUTICS, INC. · 2022-12-31 PALVELLA THERAPEUTICS, INC. (edgar:1583648) Free cash flow: -15881000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T04:36:40Z Snapshot: 02fca779942537b0a08c935bf55b3c110d58931b501aa7dca65196bda2d05b71 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1583648?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -14840000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1583648/000143774924038553/pirs20241220_s1.htm#5447087 Filing: 000143774924038553 Input fundies:CapitalExpenditure: 1041000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1583648/000143774924010123/pirs20231231_10k.htm#1271122 Filing: 000143774924010123 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	USD 18.69 million Exact value Exact value: 18691000 USD 2023-01-01 – 2023-12-31: 18691000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PALVELLA THERAPEUTICS, INC. · 2023-12-31 PALVELLA THERAPEUTICS, INC. (edgar:1583648) Net Income: 18691000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T04:36:40Z Snapshot: 02fca779942537b0a08c935bf55b3c110d58931b501aa7dca65196bda2d05b71 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1583648/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: 18691000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1583648/000095017025047212/pvla-20241231.htm#2590653 Filing: 000095017025047212 The citation records this snapshot. The page link may show a newer release later.	−USD 13.7 million Exact value Exact value: -13703000 USD 2023-01-01 – 2023-12-31: -13703000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PALVELLA THERAPEUTICS, INC. · 2023-12-31 PALVELLA THERAPEUTICS, INC. (edgar:1583648) Operating Cash Flow: -13703000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T04:36:40Z Snapshot: 02fca779942537b0a08c935bf55b3c110d58931b501aa7dca65196bda2d05b71 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1583648/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -13703000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1583648/000095017025047212/pvla-20241231.htm#2642865 Filing: 000095017025047212 The citation records this snapshot. The page link may show a newer release later.	USD 171,000 Exact value Exact value: 171000 USD 2023-01-01 – 2023-12-31: 171000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · PALVELLA THERAPEUTICS, INC. · 2023-12-31 PALVELLA THERAPEUTICS, INC. (edgar:1583648) Capital Expenditure: 171000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T04:36:40Z Snapshot: 02fca779942537b0a08c935bf55b3c110d58931b501aa7dca65196bda2d05b71 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1583648/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 171000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1583648/000143774924010123/pirs20231231_10k.htm#1270538 Filing: 000143774924010123 The citation records this snapshot. The page link may show a newer release later.	−USD 13.87 million Calculation and evidence -13703000 − 171000 USD Exact free cash flow: -13874000 USD 2023-01-01 – 2023-12-31: -13703000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 171000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · PALVELLA THERAPEUTICS, INC. · 2023-12-31 PALVELLA THERAPEUTICS, INC. (edgar:1583648) Free cash flow: -13874000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T04:36:40Z Snapshot: 02fca779942537b0a08c935bf55b3c110d58931b501aa7dca65196bda2d05b71 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1583648?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -13703000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1583648/000095017025047212/pvla-20241231.htm#2642865 Filing: 000095017025047212 Input fundies:CapitalExpenditure: 171000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1583648/000143774924010123/pirs20231231_10k.htm#1270538 Filing: 000143774924010123 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 17.43 million Exact value Exact value: -17434000 USD 2024-01-01 – 2024-12-31: -17434000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PALVELLA THERAPEUTICS, INC. · 2024-12-31 PALVELLA THERAPEUTICS, INC. (edgar:1583648) Net Income: -17434000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T04:36:40Z Snapshot: 02fca779942537b0a08c935bf55b3c110d58931b501aa7dca65196bda2d05b71 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1583648/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -17434000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1583648/000119312526133372/pvla-20251231.htm#2755327 Filing: 000119312526133372 The citation records this snapshot. The page link may show a newer release later.	−USD 10.84 million Exact value Exact value: -10840000 USD 2024-01-01 – 2024-12-31: -10840000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PALVELLA THERAPEUTICS, INC. · 2024-12-31 PALVELLA THERAPEUTICS, INC. (edgar:1583648) Operating Cash Flow: -10840000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T04:36:40Z Snapshot: 02fca779942537b0a08c935bf55b3c110d58931b501aa7dca65196bda2d05b71 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1583648/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -10840000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1583648/000119312526133372/pvla-20251231.htm#2814798 Filing: 000119312526133372 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2025 2025-01-01 – 2025-12-31	−USD 41.7 million Exact value Exact value: -41700000 USD 2025-01-01 – 2025-12-31: -41700000 USD Inspect Net Income Open source Share or cite Citation for Net Income · PALVELLA THERAPEUTICS, INC. · 2025-12-31 PALVELLA THERAPEUTICS, INC. (edgar:1583648) Net Income: -41700000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T04:36:40Z Snapshot: 02fca779942537b0a08c935bf55b3c110d58931b501aa7dca65196bda2d05b71 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1583648/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -41700000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1583648/000119312526133372/pvla-20251231.htm#2887760 Filing: 000119312526133372 The citation records this snapshot. The page link may show a newer release later.	−USD 25 million Exact value Exact value: -25000000 USD 2025-01-01 – 2025-12-31: -25000000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · PALVELLA THERAPEUTICS, INC. · 2025-12-31 PALVELLA THERAPEUTICS, INC. (edgar:1583648) Operating Cash Flow: -25000000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T04:36:40Z Snapshot: 02fca779942537b0a08c935bf55b3c110d58931b501aa7dca65196bda2d05b71 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1583648/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -25000000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1583648/000119312526133372/pvla-20251231.htm#2888616 Filing: 000119312526133372 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

107 filings · 3,278 latest values · 3,266 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001583648, 1583648, PIRS, PVLA, edgar:1583648

Also known as Marika Inc., PALVELLA THERAPEUTICS, INC., PIERIS PHARMACEUTICALS, INC., Palvella Therapeutics, Inc.

PALVELLA THERAPEUTICS, INC.

Latest quarter

Revenue

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Company performance

What changed year over year

Net income

Operating cash flow

Where revenue goes

2023 2023-01-01 – 2023-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation